تحميل
NYSEReal EstateReal Estate - Services
أحدث البيانات المتاحة
1.60 US$
+0.12 US$ · +8.11%
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
أحدث البيانات المتاحة
1.60 US$
+0.12 US$ · +8.11%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
53
قيمة عادلة
المشاعر
60
مختلط
المخاطر
62
مخاطر مرتفعة
الزخم
72
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباح | 18 ديسمبر 2009 | 0.02 US$Semi-Annual | — | 31 ديسمبر 2009 |
توزيعات الأرباح | 19 يونيو 2009 | 0.02 US$Semi-Annual | — | 30 يونيو 2009 |
استحقاق التوزيعات 18 ديسمبر 2009
0.02 US$
Semi-Annual
تاريخ الدفع 31 ديسمبر 2009
استحقاق التوزيعات 19 يونيو 2009
0.02 US$
Semi-Annual
تاريخ الدفع 30 يونيو 2009
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
